Significant association of poor glycemic control with increased resistance in efferent arterioles - Study of inulin and para-aminohippuric acid clearance in humans

Diabetes Research and Clinical Practice

Volumn 104, Issue 2, 2014, Pages 234-240

  Tsuda, A ^a   Ishimura, E ^b   Ohno, Y ^a   Ichii, M ^a   Nakatani, S ^a   Mori, K ^a   Fukumoto, S ^a   Emoto, M ^a   Inaba, M ^a  

^a Department of Endocrinology Metabolism and Molecular Medicine   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Clearance; Efferent arteriole; Glomerular hemodynamic; Inulin; Para aminohippuric acid; Type 2 diabetes

Indexed keywords

CLEARANCE; EFFERENT ARTERIOLE; GLOMERULAR HEMODYNAMIC; INULIN; PARA-AMINOHIPPURIC ACID; TYPE 2 DIABETES;

ADULT; AGED; ARTERIOLES; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INULIN; KIDNEY GLOMERULUS; MALE; MIDDLE AGED; P-AMINOHIPPURIC ACID; PROGNOSIS; RETROSPECTIVE STUDIES; SERUM ALBUMIN; VASCULAR RESISTANCE; YOUNG ADULT;

EID: 84899117792     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.01.030     Document Type: Article

References (38)

1. Collins A.J., Foley R.N., Herzog C., Chavers B., Gilbertson D., Ishani A., et al. United States renal data system 2008 annual data report. Am J Kidney Dis 2009, 53:S1-S374.
2. Ritz E., Dikow R. Hypertension and antihypertensive treatment of diabetic nephropathy. Nat Clin Pract Nephrol 2006, 2:562-567.
3. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
4. Peti-Peterdi J., Kang J.J., Toma I. Activation of the renal renin-angiotensin system in diabetes - new concepts. Nephrol Dial Transplant 2008, 23:3047-3049.
5. Lewko B., Endlich N., Kriz W., Stepinski J., Endlich K. C-type natriuretic peptide as a podocyte hormone and modulation of its cGMP production by glucose and mechanical stress. Kidney Int 2004, 66:1001-1008.
6. Arima S., Ito S. The mechanisms underlying altered vascular resistance of glomerular afferent and efferent arterioles in diabetic nephropathy. Nephrol Dial Transplant 2003, 18:1966-1969.
7. Kanwar Y.S., Wada J., Sun L., Xie P., Wallner E.I., Chen S., et al. Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med (Maywood) 2008, 233:4-11.
8. Helal I., Fick-Brosnahan G.M., Reed-Gitomer B., Schrier R.W. Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat Rev Nephrol 2012, 8:293-300.
9. Gomez D.M. Evaluation of renal resistances, with special reference to changes in essential hypertension. J Clin Invest 1951, 30:1143-1155.
10. Guidi E., Cozzi M.G., Minetti E.E., Civati G., Busnach G., Brando B. Effect of familial hypertension on glomerular hemodynamics and tubulo-glomerular feedback after uninephrectomy. Am J Hypertens 2001, 14:121-128.
11. Diagnosis and classification of diabetes mellitus. Diabetes Care 2013, 36(Suppl. 1):S67-S74.
12. Nakao T., Sanaka T., Tsubakihara Y., Hattori M., Honda M., Mizuiri S., et al. Dietary recommendations for chronic kidney disease, 2007. Nihon Jinzo Gakkai Shi 2007, 49:871-878.
13. Treatment guide for diabetes 2007, Bunkodo, Tokyo. Japan Diabetes Society (Ed.).
14. Horio M., Imai E., Yasuda Y., Hishida A., Matsuo S. Simple sampling strategy for measuring inulin renal clearance. Clin Exp Nephrol 2009, 13:50-54.
15. Tsuda A., Inaba M., Ichii M., Ochi A., Ohno Y., Nakatani S., et al. Relationship between serum TSH levels and intrarenal hemodynamic parameters in euthyroid subjects. Eur J Endocrinol 2013, 169:45-50.
16. Tsuda A., Ishimura E., Ohno Y., Ichii M., Nakatani S., Machida Y., et al. Poor glycemic control is a major factor in the overestimation of glomerular filtration rate in diabetic patients. Diabetes Care 2013, [ePub ahead of Print October 15, 2013].
17. Kimata S., Mizuguchi K., Hattori S., Teshima S., Orita Y. Evaluation of a new automated, enzymatic inulin assay using d-fructose dehydrogenase. Clin Exp Nephrol 2009, 13:341-349.
18. Fliser D., Dikow R., Demukaj S., Ritz E. Opposing effects of angiotensin II on muscle and renal blood flow under euglycemic conditions. J Am Soc Nephrol 2000, 11:2001-2006.
19. Turner S.T., Reilly S.L. Fallacy of indexing renal and systemic hemodynamic measurements for body surface area. Am J Physiol 1995, 268:R978-R988.
20. Komers R., Schutzer W., Xue H., Oyama T.T., Lindsley J.N., Anderson S. Effects of p38 mitogen-activated protein kinase inhibition on blood pressure, renal hemodynamics, and renal vascular reactivity in normal and diabetic rats. Transl Res 2007, 150:343-349.
21. Hostetter T.H., Rennke H.G., Brenner B.M. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982, 72:375-380.
22. Komers R., Anderson S. Are angiotensin-converting enzyme inhibitors the best treatment for hypertension in type 2 diabetes?. Curr Opin Nephrol Hypertens 2000, 9:173-179.
23. Hayashi K., Epstein M., Loutzenhiser R., Forster H. Impaired myogenic responsiveness of the afferent arteriole in streptozotocin-induced diabetic rats: role of eicosanoid derangements. J Am Soc Nephrol 1992, 2:1578-1586.
24. Vidotti D.B., Casarini D.E., Cristovam P.C., Leite C.A., Schor N., Boim M.A. High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells. Am J Physiol Renal Physiol 2004, 286:F1039-F1045.
25. Wiseman M.J., Mangili R., Alberetto M., Keen H., Viberti G. Glomerular response mechanisms to glycemic changes in insulin-dependent diabetics. Kidney Int 1987, 31:1012-1018.
26. Ishida K., Ishibashi F., Takashina S. Comparison of renal hemodynamics in early non-insulin-dependent and insulin-dependent diabetes mellitus. J Diabet Complications 1991, 5:143-145.
27. Miller J.A. Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus. J Am Soc Nephrol 1999, 10:1778-1785.
28. Leehey D.J., Singh A.K., Alavi N., Singh R. Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl 2000, 77:S93-S98.
29. Visavadiya N.P., Li Y., Wang S. High glucose upregulates upstream stimulatory factor 2 in human renal proximal tubular cells through angiotensin II-dependent activation of CREB. Nephron Exp Nephrol 2011, 117:e62-e70.
30. Nishiyama A., Seth D.M., Navar L.G. Renal interstitial fluid angiotensin I and angiotensin II concentrations during local angiotensin-converting enzyme inhibition. J Am Soc Nephrol 2002, 13:2207-2212.
31. Singh R., Singh A.K., Alavi N., Leehey D.J. Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose. J Am Soc Nephrol 2003, 14:873-880.
32. Cherney D.Z., Reich H.N., Miller J.A., Lai V., Zinman B., Dekker M.G., et al. Age is a determinant of acute hemodynamic responses to hyperglycemia and angiotensin II in humans with uncomplicated type 1 diabetes mellitus. Am J Physiol Regul Integr Comp Physiol 2010, 299:R206-R214.
33. Kelly D.J., Zhang Y., Moe G., Naik G., Gilbert R.E. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 2007, 50:2398-2404.
34. Feldman D.L., Jin L., Xuan H., Contrepas A., Zhou Y., Webb R.L., et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008, 52:130-136.
35. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
36. Viberti G., Wheeldon N.M. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002, 106:672-678.
37. Kowey P.R., Dickson T.Z., Zhang Z.X., Shahinfar S., Brenner B.M., Investigators R. Losartan and end-organ protection-lessons from the RENAAL study. Clin Cardiol 2005, 28:136-142.
38. Deferrari G., Ravera M., Deferrari L., Vettoretti S., Ratto E., Parodi D. Renal and cardiovascular protection in type 2 diabetes mellitus: angiotensin II receptor blockers. J Am Soc Nephrol 2002, 13(Suppl. 3):S224-S229.